Obinutuzumab

Tax included
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
MedChemExpress 
HY-P9910

Data sheet

Size
Multiple sizes
Reactivity
CD20
Application
Cancer-programmed cell death
CAS
949142-50-1